Mnemosyne Pharmaceuticals, Inc. is a privately-held, biotechnology company focused on the discovery and development of small molecule therapeutics for the neuropsychiatry market. The company's drug discovery efforts are focused on targeting the NMDA receptor, which is known to be the 'master' switch for learning and memory.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/02/13 | $6,000,000 | Series A-2 |
Atlas Venture Clal Biotechnology Industries | undisclosed |
